



Published in final edited form as:

Nature. 2022 September ; 609(7925): 159–165. doi:10.1038/s41586-022-04934-4.

Zbtb46 defines and regulates ILC3s that protect the intestine

Wenqing Zhou^{1,2,3}, Lei Zhou^{1,2,3}, Jordan Zhou^{1,2,3}, JRI Live Cell Bank³, Coco Chu³, Chao Zhang⁴, Robbyn E. Sockolow⁵, Gerard Eberl⁶, Gregory F. Sonnenberg^{1,2,3,*}

¹Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology, Weill Cornell Medicine, Cornell University, New York, NY, USA

²Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA

³Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA

⁴Department of Medicine, Division of Computational Biomedicine, Boston University, Boston, MA, USA

⁵Department of Pediatrics, Division of Gastroenterology and Nutrition, Weill Cornell Medicine, Cornell University, New York, NY, USA

⁶Microenvironment & Immunity Unit, Institut Pasteur, Paris, France

Abstract

ROR γ t is a lineage-specifying transcription factor expressed by immune cells that are enriched in the gastrointestinal tract and orchestrate immunity, inflammation, and tissue homeostasis^{1–15}. However, fundamental questions remain regarding the cellular heterogeneity among these cell types, the mechanisms controlling protective versus inflammatory properties, and their functional redundancy. Here, we define all ROR γ t⁺ immune cells in the intestine at single cell resolution and unexpectedly identify a subset of group 3 innate lymphoid cells (ILC3s) expressing Zbtb46, a transcription factor that specifies conventional dendritic cells (cDCs)^{16–20}. Zbtb46 is robustly expressed by CCR6⁺ lymphoid tissue inducer (LTi)-like ILC3s that are developmentally and phenotypically distinct from cDCs, and expression is imprinted by ROR γ t, fine-tuned by microbiota-derived signals, and increased by pro-inflammatory cytokines. Zbtb46 uniquely functions to restrain inflammatory properties of ILC3s, including OX40L-dependent expansion of Th17 cells and exacerbated intestinal inflammation following enteric infection. Finally, Zbtb46⁺ ILC3s are a dominant source of IL-22, and selective depletion of this population renders mice susceptible to enteric infection and associated intestinal inflammation. These results define an unexpected transcription factor shared between cDCs and ILC3s, a cell-intrinsic function for

*Correspondence: Correspondence and requests for materials should be addressed to gfsonnenberg@med.cornell.edu.

Author contributions

W.Z. and G.F.S. conceived the project. W.Z. performed most experiments and analyzed the data. L.Z., J.Z., and C.C. helped with experiments and data analyses. R.E.S. and JRI Live Cell Bank contributed to clinical sample acquisition and processing. C.Z. performed bioinformatic analyses. G.E. provided essential mouse models, scientific advice, and expertise. W.Z. and G.F.S. wrote the manuscript, with input from all the authors.

The authors declare no competing interests.

Zbtb46 in restraining pro-inflammatory properties of ILC3s, and a non-redundant role for Zbtb46⁺ ILC3s in orchestrating intestinal health.

ROR γ t is a lineage-specifying transcription factor for immune cell populations that are enriched in the intestine, including T helper (Th)17 cells, regulatory T (Treg) cells, γ δ T cell subsets, and group 3 innate lymphoid cells (ILC3s)^{1–15}. Fundamental research has defined that these ROR γ t⁺ lymphocytes are critical to maintain intestinal homeostasis and mediate essential immunity against infections^{1–15}. However, dysregulation of these cells drives pathogenic intestinal inflammation and other chronic inflammatory diseases. Translational studies have found dysregulated cell numbers and cytokine profiles of ROR γ t⁺ immune cells in the intestine of patients with inflammatory bowel disease (IBD) and colorectal cancer^{21–24}. Despite these advances, the full spectrum of cellular heterogeneity, regulatory pathways, and potential functional redundancy of ROR γ t⁺ immune cells in the intestine remains poorly defined.

CCR6⁺ ILC3s robustly express Zbtb46

To address these fundamental gaps in knowledge, we performed single-cell RNA sequencing (scRNA-seq) on all ROR γ t expressing immune cells in the large intestine of healthy mice. ROR γ t⁺ immune cells were sorted from ROR γ t^{EGFP} mice and mixed at a 1:1 ratio of TCR β ⁺ cells to TCR β ⁻ cells, permitting dual analysis of conventional T cells and non-T cells (Extended data Fig. 1a). Ten distinct cell clusters of ROR γ t expressing cells were identified, and one was excluded due to a lack of *Rorc* transcripts (Fig. 1a, b). Based on the expression of *Cd3e*, clusters 0, 1, 2, 6, 8 and 9 represent T cells, while clusters 3, 4, 5 and 7 represent non-T cells (Fig. 1b). We analyzed signature genes expressed by each cluster and identified that T cell clusters contain ROR γ t⁺ Treg (*Trac*⁺ *Foxp3*⁺), Th17 cell (*Trac*⁺ *Il17a*⁺) and γ δ T cell (*Trdc*⁺) subsets (Fig. 1c). Non-T cell clusters were all ILC subsets based on high expression of *Thy1* and *Il7r*, including T-bet⁺ ILC3s (NKp46⁺ ILC3s), CCR6⁺ ILC3s (lymphoid tissue-inducer (LTI)-like ILC3s), CCR6⁻ T-bet⁻ ILC3s (double negative or DN ILC3s) and a minor population of group 2 ILCs (ILC2s, *Gata3*⁺ *Klrg1*⁺) (Fig. 1c). These data provide a comprehensive single cell atlas of all ROR γ t⁺ immune cells in the healthy mammalian intestine.

Beyond these well-described innate and adaptive lymphocytes, it was recently suggested that a subset of conventional dendritic cells (cDCs) in the spleen express ROR γ t²⁵. However, examination of non-T cell clusters revealed an absence of cDC-specific transcripts, including *Itgax*, *Flt3*, *Xcr1*, and *Sirpa* (Fig. 1d) and experiments with ROR γ t reporter mice, fate mapping mice, and protein staining revealed that intestinal cDCs do not express ROR γ t (Extended data Fig. 1b, 1c, 2a, b, c). Surprisingly, in the analysis of cDC-specific markers, we unexpectedly observed that the cluster of CCR6⁺ ILC3s expresses *Zbtb46* (Fig. 1d), a transcription factor identified by two independent groups as a specific marker for cDCs and their progenitors^{16,17}. We confirmed *Zbtb46* expression in ILC3s by examining *Zbtb46* mRNA levels among different immune cells in the intestine. As expected, cDCs have the highest expression level of *Zbtb46*, but significant expression is also observed in ILC3s, whereas other immune cell types like ILC2s, macrophages (Mac), CD4⁺ T cells and B cells

showed negligible expression levels (Fig. 1e). This was further confirmed using *Zbtb46^{GFP+}* reporter mice, which revealed that ILC3s abundantly express *Zbtb46-GFP* in the large intestine (Fig. 1f). The frequency of *Zbtb46-GFP⁺* cells in ILC3s is comparable to that of cDCs and is notably enriched in the CCR6⁺ ILC3 subset, while minor proportion of DN ILC3s and NKp46⁺ ILC3s express *Zbtb46-GFP* (Fig. 1g, h, and Extended data Fig. 3a–d). Minimal *Zbtb46-GFP⁺* cells are observed in ILC2s, CD4⁺ T cells, or $\gamma\delta$ T cells (Fig. 1f, g, and Extended data Fig. 4a). *Zbtb46* is also expressed in CCR6⁺ ILC3s, but not in other ILC subsets or CD4⁺ T cells, across multiple mucosal and lymphoid tissues, including the small intestine, skin, lung, adipose tissues, salivary glands, spleen, and peripheral lymph nodes (Extended data Fig. 4c). The expression of *Zbtb46* in CCR6⁺ ILC3s, but not in T cell subsets, is further confirmed by fate mapping with *Zbtb46^{cre}ROSA26^{Isl-EYFP}* mice and protein staining in both the small and large intestine (Fig. 1i–k and Extended data Fig. 1c, 3e, 3f, 4b). ILC3s from the human intestine also abundantly express ZBTB46 transcripts and protein relative to other immune cell subsets (Fig. 1l, m, and Extended Data Fig. 5). These data demonstrate that in addition to cDCs, *Zbtb46* is robustly expressed by the CCR6⁺ LTi-like subset of ILC3s.

Zbtb46⁺ ILC3s are distinct from cDCs

The expression of *Zbtb46* among the CCR6⁺ subset of ILC3s provokes questions related to their phenotype, ontogeny, and function relative to cDCs. This subset of ILC3s in the intestine exhibited low staining for cDC-specific markers *Xcr1*, *CD172a*, *Irf8* and *Irf4* (Fig. 2a). Further, fate-mapping analyses showed that intestinal cDCs were efficiently marked by *Csf1r^{Cre}*, *Itgax^{Cre}*, *Clec9a^{Cre}*, and *Zbtb46^{Cre}*, but not by *Il7r^{Cre}*, *Rorc^{Cre}*, and *Il22^{Cre}* (Fig. 2b, Extended data Fig. 2c, 6a). In contrast, *Il7r^{Cre}*, *Rorc^{Cre}*, *Il22^{Cre}*, and *Zbtb46^{Cre}*, but not *Csf1r^{Cre}*, *Itgax^{Cre}*, and *Clec9a^{Cre}*, marked the majority of CCR6⁺ ILC3s (Fig. 2b, Extended data Fig. 2c, 6a). As *Zbtb46* and *Clec9a* are markers for cDC progenitors^{16,17,26}, we examined for expression of *Zbtb46* in ILC3 progenitor cells in the bone marrow. However, *Zbtb46* was not detected in conventional ILC progenitors, including common helper ILC progenitors (CHILP), ILC progenitors (ILCP), or LTi cell progenitors (LTiP) (Fig. 2c). Further, well-defined cDC precursors (pre-DC) or CHILP were sorted from the bone marrow of *Zbtb46^{GFP+}* reporter mice and transferred into lymphopenic *Rag2^{-/-}Il2rg^{-/-}* recipient mice (Extended data Fig. 6b). *Zbtb46⁺* ILC3s differentiated only from *Zbtb46*-negative CHILPs but not *Zbtb46⁺* pre-DCs (Fig. 2d, Extended data Fig. 6c), suggesting that ILC3s acquire *Zbtb46* upon maturation. These data demonstrate that *Zbtb46⁺* ILC3s are phenotypically and developmentally distinct from cDCs.

Factors regulating Zbtb46 in ILC3s

We next sought to understand what regulates *Zbtb46* expression in ILC3s. We found that fetal LTi cells express *Zbtb46* in both the fetal gut and liver, while their immediate progenitors are predominantly negative, indicating that *Zbtb46* expression is imprinted early in LTi cell ontogeny and upon maturation (Fig. 2e–g, Extended data Fig. 6d). Using previously published assay for transposase-accessible chromatin using sequencing (ATAC-seq) data²⁷, we found a ROR γ t (RORE) motif binding site in the *Zbtb46* locus of CCR6⁺ ILC3s and that *ex vivo* culture of CCR6⁺ ILC3s with a small molecule inhibitor of ROR γ t

was sufficient to reduce *Zbtb46* expression (Extended data Fig. 6e,f). We were unable to identify T-bet binding motifs in the *Zbtb46* locus and no impact of T-bet deletion on *Zbtb46* expression in ILC3s was observed (Extended data Fig. 6g). These data indicate that ROR γ t supports *Zbtb46* expression in ILC3s upon maturation.

Due to the importance of the microbiota in ILC3 function²⁸, we also examined the expression of *Zbtb46* in ILC3s from the intestine of germ-free (GF) mice and conventional specific pathogen free (SPF) mice. CCR6⁺ ILC3s sorted from GF mice express significantly higher levels of *Zbtb46* relative to those from SPF mice and the colonization of GF mice with conventional microbiota (ex-GF) was sufficient to reduce *Zbtb46* expression (Fig. 2h). Consistently, *Zbtb46*^{GFP+} reporter mice treated with broad-spectrum antibiotics (ABX) displayed significantly increased frequencies of *Zbtb46*⁺ CCR6⁺ ILC3s in the large intestine (Fig. 2i). This effect was also observed in double negative ILC3s and NKp46⁺ ILC3s (Fig. 2h, i, Extended data Fig. 6h). These data suggest that the expression of *Zbtb46* in ILC3s is modulated following colonization with microbiota. Of note, sex hormones can also impact *Zbtb46* expression²⁹, and slightly higher *Zbtb46* expression levels were observed in ILC3 subsets from female mice relative to male mice (Extended data Fig. 4d).

A previous study identified that the genomic loci harboring *ZBTB46* is associated with pediatric IBD and that the expression of *ZBTB46* is significantly increased in total colonic tissue biopsies from IBD patients³⁰. We therefore tested whether ILC3-intrinsic *Zbtb46* expression is altered during intestinal inflammation. We first observed that *Zbtb46* is significantly elevated in CCR6⁺ ILC3s from the large intestine of *Il10*^{-/-} mice which exhibit spontaneous intestinal inflammation relative to co-housed controls (Fig. 2j). Furthermore, the inflammatory cytokines, IL-1 β and TL1A, are sufficient to significantly increase *Zbtb46* expression in *ex vivo* CCR6⁺ ILC3 cultures (Fig. 2k). Further, we investigated a cohort of pediatric IBD patients, including both Ulcerative colitis (UC) and Crohn's disease (CD) patients (Supplemental Table 1), and observed a significant increase in *ZBTB46* protein among ILC3s relative to those from sex- and age-matched healthy controls (Fig. 2l). A significant correlation between *ZBTB46* levels in ILC3s and UC disease activity scores was also observed (Extended data Fig. 6i). These data demonstrate that expression of *Zbtb46* is imprinted at late stages of differentiation, modulated by microbial stimuli or inflammatory cytokines, and altered in human IBD.

Zbtb46 limits ILC3-mediated inflammation

We next examined the functional significance of *Zbtb46* in ILC3s, as it has previously been found to regulate the activation of cDCs³¹. This was accomplished by crossing *Zbtb46*-floxed mice with *Rorc*^{Cre} mice to generate a conditional *Zbtb46* deficiency. *Zbtb46* expression was significantly reduced in CCR6⁺ ILC3s in *Rorc*^{Cre}*Zbtb46*^{fl/fl} mice, while no impacts on *Zbtb46* expression were observed in cDCs or T cells (Fig. 3a, Extended data Fig. 7a–d). Comparable frequencies, subset distribution, cytokine production, MHCII expression, and lymphoid organogenesis functions of ILC3s were detected in mice with a lineage-specific deletion of *Zbtb46* (Fig. 3b, c, Extended data Fig. 7e–m). However, transcriptome comparison revealed a selective upregulation of proinflammatory pathways in *Zbtb46*-deficient ILC3s relative to those from littermate controls (Extended data Fig.

7n). Interestingly, Zbtb46-deficient CCR6⁺ ILC3s exhibited a notable increase in *Tnfrsf4*, *Ptgs2* and *Il6* transcripts, which were confirmed by transcript quantification or protein staining (Fig. 3d–g, Extended data Fig. 7o, Supplementary Table 2). Moreover, re-analysis of existing ATAC-seq data from intestinal CCR6⁺ ILC3s²⁷ showed putative Zbtb46 binding sites in the *Tnfrsf4* and *Ptgs2* loci (Extended data Fig. 7p). We then sought to interrogate the biological significance of the enhanced proinflammatory properties of ILC3s in the intestine of *Rorc^{Cre}Zbtb46^{fl/fl}* mice. Since OX40L (encoded by *Tnfrsf4*)^{32,33} and COX-2 (encoded by *Ptgs2*)^{34,35} are associated with promoting the activation and function of T effector cells, we examined adaptive immunity in the large intestine of *Rorc^{Cre}Zbtb46^{fl/fl}* mice and observed a significantly increased frequency of Th17 cells and associated IL-17A production relative to littermate controls (Fig. 3h, i). We generated a mixed bone marrow chimera between wild type and Zbtb46-deficient mice and observed a striking increased expansion of Zbtb46-deficient ILC3s relative to Zbtb46-sufficient ILC3s, while T cell responses were comparable in the intestine between the two genotypes (Extended data Fig. 8a–g). No phenotype was observed in *CD4^{Cre}Zbtb46^{fl/fl}* mice (Extended data Fig. 8h–j). These data demonstrate a cell-intrinsic role for Zbtb46 in ILC3s but not T cells. Furthermore, transient *in vivo* blockade of OX40L with a neutralization antibody is sufficient to prevent the upregulated Th17 cell response in the intestine of *Rorc^{Cre}Zbtb46^{fl/fl}* mice relative to littermate controls (Fig. 3j, k), indicating that Zbtb46 restrains the pro-inflammatory functions of CCR6⁺ ILC3s in part by controlling the expression of the co-stimulatory molecule OX40L. Next, we tested whether ILC3-specific Zbtb46 impacts intestinal inflammation by infecting *Rorc^{Cre}Zbtb46^{fl/fl}* mice and their littermate controls with the enteric pathogen, *Citrobacter rodentium*. No alterations in Zbtb46 expression among cDCs or T cells occurred in this context, and comparable ILC3 subset composition, proliferation, and cytokine production (including IL-22 levels) was observed after *C. rodentium* infection (Extended data Fig. 8k–s). However, significantly increased Th17 cells and associated IL-17A production were observed in the large intestine of *Rorc^{Cre}Zbtb46^{fl/fl}* mice (Fig. 3l, m). Further, *Rorc^{Cre}Zbtb46^{fl/fl}* mice also displayed significantly increased bacterial burdens, shorter colon length, and more severe inflammation-associated pathology, including increased immune cell infiltration, elongated colonic crypts, and disrupted epithelial structures, relative to littermate controls (Fig. 3n–p). Taken together, these data demonstrate that Zbtb46 functions to restrain the proinflammatory properties of CCR6⁺ ILC3s and protect from intestinal inflammation.

Zbtb46⁺ ILC3s protect the intestine

Prior reports suggest functional redundancy among ROR γ t⁺ lymphocytes^{36–38}. Our discovery of Zbtb46⁺ ILC3s allows new opportunities to determine their functional significance and potential redundancy with other ROR γ t⁺ immune cells. To further investigate the function of Zbtb46⁺ ILC3s, we examined our single-cell RNA sequencing data and identified that *Il22* is specifically and highly enriched among Zbtb46⁺ ILC3s over other ROR γ t⁺ immune cells (Fig. 4a, Extended data Fig. 9a). Using IL-22 protein staining, *Il22*-eGFP reporter mice, and *Il22^{Cre}* fate-mapping mice, we further confirmed that IL-22 is dominantly produced by Zbtb46⁺ CCR6⁺ ILC3s in the large intestine (Fig. 4b, c, Extended data Fig. 9b–d). Zbtb46 is specifically expressed by cDCs and ILC3s, and ROR γ t is not expressed by Zbtb46⁺ cDCs or endothelial cells in the intestine (Extended data Fig. 2).

Therefore, we crossed ROR γ t-floxed mice with *Zbtb46*^{Cre} mice to generate an exclusive deletion of ROR γ t in *Zbtb46*⁺ ILC3s and to define the functional role of *Zbtb46*⁺ ILC3s in intestinal health and disease. ILC3 frequency, particularly among the CCR6⁺ ILC3 subset, was significantly reduced in the large intestine of *Zbtb46*^{Cre}*Rorc*^{fl/fl} mice relative to the littermate controls at steady state, while the frequencies of cDCs and other immune cells were not affected (Fig. 4d–h, Extended data 9e–k). As expected, the innate source of IL-22 was significantly decreased in *Zbtb46*^{Cre}*Rorc*^{fl/fl} mice relative to littermate controls, while T cell-derived IL-22 was not impacted (Extended data Fig. 9l–n). We also observed that loss of ROR γ t significantly reduced *Zbtb46* expression in ILC3s (Extended data Fig. 10a–f), further indicating that ROR γ t modulates *Zbtb46* expression in ILC3s.

We next investigated whether *Zbtb46*⁺ ILC3s play a unique role in regulating intestinal immunity or inflammation by infecting mice with *C. rodentium*. The frequency of ILC3s and CCR6⁺ ILC3s remained decreased in the large intestine of *Zbtb46*^{Cre}*Rorc*^{fl/fl} mice after infection (Fig. 4i, j, Extended data Fig. 9o) and a significant increase in bacterial burden was observed in the feces (Fig. 4k). Despite the essential role of IL-22 in immunity to *C. rodentium*^{39–41} and the dominant role of *Zbtb46*⁺ ILC3s in producing IL-22 in the healthy intestine, *Zbtb46*^{Cre}*Rorc*^{fl/fl} mice exhibited only a modest reduction in survival following infection (Extended data Fig. 9p). This may result from the remaining IL-22 produced by ROR γ t-negative ILCs or residual CCR6⁺ LTi-like ILC3s in *Zbtb46*^{Cre}*Rorc*^{fl/fl} mice (Extended data Fig. 9l–m), or a potential compensation by other IL-22-producing cell types^{42,43}. In support of the latter, Th17 cells, but not $\gamma\delta$ T cells, were significantly increased in *Zbtb46*^{Cre}*Rorc*^{fl/fl} mice following *C. rodentium* infection (Fig. 4l, m, Extended data Fig. 9q). While compensating for impaired innate immunity, this elevated local Th17 cell response could exacerbate intestinal inflammation⁴⁴. Indeed, severe inflammation-associated pathology, including enhanced leukocyte infiltration and elongated colonic crypts, as well as a significant reduction in colon length, was observed in mice lacking *Zbtb46*⁺ ILC3s after *C. rodentium* infection (Fig. 4n, o). These data collectively demonstrate that *Zbtb46*⁺ ILC3s have an essential and non-redundant role in controlling intestinal inflammation induced by bacterial infection.

ROR γ t expressing immune cells are critical to maintain intestinal health and homeostasis but, when dysregulated, are major drivers of intestinal inflammation^{1–15}. Our results provide a comprehensive single cell atlas of the complete cellular heterogeneity among ROR γ t expressing immune cells in the intestine. We identify an absence of ROR γ t⁺ cDCs, and rather that the CCR6⁺ or LTi-like ILC3 subset expresses *Zbtb46*, a transcriptional regulator employed by cDCs. This further elaborates on the transcriptional networks in the ILC3 family and represents a fundamental advance as *Zbtb46* was previously thought to be restricted to cDCs in the mammalian immune system and is widely utilized to probe the function of cDCs in immunity, inflammation, and tolerance^{16–20}. Further, *Zbtb46* functionally restricts the pro-inflammatory properties of CCR6⁺ ILC3s in mice, and this repressive transcription factor critically limits the ability of these ILC3s to contribute to tissue inflammation (Extended data Fig. 10g). While multiple pro-inflammatory pathways become overexpressed upon loss of *Zbtb46* in ILC3s, it is notable that several are associated with co-stimulation such as OX40L, suggesting potential overlap for *Zbtb46* in restraining the inflammatory potential of both cDCs and ILC3s as it relates to antigen presentation

and interactions with adaptive immunity. However, further investigations are required to determine whether Zbtb46 regulates the chromatin landscape and pathways shared by cDCs and ILC3s. Zbtb46 is also overexpressed in the inflamed intestine of IBD patients, which could contribute to the overall reduction of ILC3s observed in IBD^{22,45}, since in some contexts overexpression of Zbtb46 reduces cell proliferation⁴⁶. Thus, Zbtb46 could represent a novel therapeutic target for the development of small molecules geared towards treating inflammatory diseases. Finally, our findings define that the Zbtb46⁺ subset of ILC3s are essential and non-redundant in controlling intestinal inflammation, demonstrating functional dichotomy of ROR γ ⁺ lymphocytes in the context of intestinal health, enteric infections and IBD.

Materials and methods

No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.

Mice.

C57BL/6 mice were obtained from Jackson Laboratories and used at 6-12 weeks of age. Both female and male mice were used in this study. All transgenic mice were bred and maintained in specific pathogen-free facilities with 12-hour light/dark cycle, an average ambient temperature of 21°C, and an average humidity of 48% at Weill Cornell Medicine and littermates were used as controls in all experiments. *ROR γ -EGFP* and *Rorc^{Cre}* mice on C57BL/6 background were provided by G.E. *Zbtb46^{GFP/GFP}* (JAX no. 027618)¹⁶, *Csf1r^{Cre}* (JAX no. 029206)⁴⁷, *CD11c^{Cre}* (JAX no. 008068)⁴⁸, *Clec9a^{Cre}* (JAX no. 025523)²⁶, *IL22^{Cre}* (JAX no. 027524)⁴⁹, *ROSA26^{Isl-EGFP}* (JAX no. 006148)⁵⁰, *Rorc^{fl/fl}* (JAX no. 008771)⁵¹, IL22-eGFP reporter (JAX no. 035005)²³, *Tbx21^{-/-}* (JAX no. 004648)⁵², *Il10^{-/-}* (JAX no. 002251)⁵³, *CD4^{Cre}* (JAX no. 022071)⁵⁴, *Zbtb46^{Cre}* (JAX no. 028538)⁵⁵ and *Zbtb46^{fl/fl}* (JAX no. 026850)³¹ were purchased from Jackson Laboratories. *Rag2^{-/-}Il2rg^{-/-}* mice (TAC no. 4111) were purchased from Taconic. *Il7^{Cre}* mice⁵⁶ were kindly provided by Dr. Artis (Weill Cornell Medicine) with permission from H.R. Rodewald. C57BL/6 germ-free mice were maintained at the gnotobiotic facility at Weill Cornell Medicine. Sex- and age-matched mice were used for all experiments. All experiments were approved and performed according to the Institutional Animal Care and Use Committee guidelines at Weill Cornell Medicine.

Isolation of lamina propria immune cells from the intestine of mice and humans.

Whole large intestine or small intestine were dissected from mice. Mesenteric fat tissue and Peyer's patches on the small intestine were carefully removed. Intestines were opened longitudinally and extensively cleaned with cold DPBS (Corning). Intestine tissue was cut into approximately 0.5-cm sections. To dissociate epithelial cells, intestine tissue was incubated in HBSS with 5 mM EDTA (Thermo Fisher Scientific), 1 mM DTT (Sigma Aldrich), and 2% FBS twice at 37°C for 20 minutes. After incubation, the tissue was vortexed, transferred to digestion buffer containing dispase (0.4 U/ml; Thermo Fisher Scientific), collagenase III (1 mg/ml; Worthington), DNase I (20 μ g/ml; Sigma-Aldrich), and 10% FBS in RPMI 1640 (Corning), and incubated in a shaker with 200 rpm for 1

hour at 37°C. Leukocytes were enriched by a 40/80% Percoll (GE Healthcare) gradient centrifugation.

To quantify ZBTB46 protein levels, intestinal biopsies from the colon of pediatric individuals with Ulcerative colitis or Crohn's disease and sex- and age-matched controls with no inflammatory bowel disease were obtained following Institutional-Review-Board-approved protocols from the JRI IBD Live Cell Bank Consortium at Weill Cornell Medicine (protocol number 1503015958). Informed consent was obtained from all subjects. Biopsies were cryopreserved in 90% FBS and 10% DMSO for future side-by-side comparisons. Following thawing, biopsy tissues were digested in RPMI 1640 with Collagenase D (0.5 mg/ml; Roche), DNase I (20 µg/ml), and 5% FBS for 1 hour at 37°C with shaking. After digestion, remaining tissues were further dissociated mechanically by a syringe plunger. Cells were filtered through a 70 µm cell strainer and used directly for staining.

For human tonsils and intestinal resections, samples were provided by the Cooperative Human Tissue Network (CHTN), which is funded by the National Cancer Institute. Other investigators may have received specimens from the same subjects. Samples were provided as entirely de-identified human specimens with diagnoses confirmed by medical records and trained pathologists. This protocol was reviewed by the Weill Cornell Medicine IRB and determined to meet the Exemption Category 4 of HHS 45 CFR 46.104(d). Additional oversight of the CHTN is outlined at www.chtn.org. Tonsils were dissociated mechanically by a syringe plunger and cells were filtered through 70 µm cell strainer and cryopreserved in 90% FBS and 10% DMSO for a future side-by-side comparison. Following thawing, cells were used directly for staining.

To quantify *ZBTB46* expression in human intestinal immune cells, surgical-resection samples from either the non-inflamed small intestine or the colon were provided by the CHTN. Other investigators may have received specimens from the same subjects. Intestinal resections were first incubated in stripping buffer (1 mM EDTA, 1 mM DTT, and 5% FBS in RPMI 1640) at 37°C with shaking for 30 minutes to remove epithelial layer. Intestinal tissues were then minced by sterile scalpel and digested in RPMI 1640 with Collagenase D (0.5 mg/ml), DNase I (20 µg/ml), and 5% FBS for 1 hour at 37°C with shaking. After digestion, remaining tissues were further dissociated mechanically by a syringe plunger. Cells were filtered through a 70 µm cell strainer and cryopreserved in 90% FBS and 10% DMSO for future side-by-side comparisons. Following thawing, cells were used directly for surface staining and sorting.

Cell isolation from the lung, adipose tissue, skin, and salivary gland.

Lungs were chopped and incubated in RPMI medium supplemented with Liberase™ (50 µg/ml; Roche) and DNaseI (20 µg/ml) for 1 hour at 37°C. The remaining tissues were mashed with a syringe plunger, and single-cell suspensions were filtered through a 40µm cell strainer. Leukocytes were then further enriched by 40% Percoll gradient centrifugation, and red blood cells were lysed with TheraPEAK™ ACK lysis buffer (Lonza). For adipose tissue, perigonadal white adipose tissues were harvested and digested in collagenase type II (1 mg/ml; collagenase from *Clostridium histolyticum*, Sigma-Aldrich, C6885-5G) in Dulbecco's modified Eagle's medium (DMEM) (Gibco) at 37°C with shaking at 200 rpm

for 45 min. Digested tissues were filtered through a 70 μm strainer and centrifuged at 600g for 10 min. Floating adipocytes were removed, and red blood cells were lysed with TheraPEAK™ ACK lysis buffer (Lonza). To isolate cells from the skin, ears were cut, minced, and digested in 400 $\mu\text{g}/\text{ml}$ Liberase™ (Sigma 5401119001) and 60 $\mu\text{g}/\text{ml}$ DNaseI (Sigma) in 10% FBS for 90 min at 37°C under agitation. After digestion, the cell suspension was passed through a 70 μm cell strainer and used for directly staining. For salivary gland, submandibular and sublingual glands were isolated, cut into small pieces, and digested with 1 mM collagenase D, 5 mM CaCl_2 in 10% FBS RPMI 1640 buffer for 1 hour at 37°C with shaking. Cells were passed through a 70 μm cell strainer, and immune cells were enriched by 40/80% Percoll (GE Healthcare) gradient centrifugation.

Cell isolation from fetal gut and fetal liver.

Fetal gut was isolated from embryos at E14.5 under a dissecting microscope. Tissue was cut into small pieces and digested with 25 $\mu\text{g}/\text{ml}$ Liberase™ (Sigma 5401119001) and 50 $\mu\text{g}/\text{ml}$ DNaseI (Sigma) in 10% FBS for 1 hour at 37°C under agitation. After digestion, remaining tissues were further dissociated mechanically by a syringe plunger. Cells were filtered through a 70 μm cell strainer and used directly for staining. Intestine from 2 embryos were pooled together as one sample. For fetal liver, tissue from E14.5 embryos was dissociated by vigorously pipetting using a 1,000 μl pipette. Cell suspension was then filtered through 70 μm strainer, washed with FACS buffer followed by red blood cell lysis using TheraPEAK™ ACK lysis buffer (Lonza).

Flow cytometry and cell sorting.

Single cell suspensions were first blocked with anti-CD16/32 antibody (BD Biosciences, 2.4G2) and then incubated on ice with conjugated antibodies in PBS containing 1% FBS and 0.25mM EDTA. Dead cells were excluded by Fixable Aqua Dead Cell Stain (Thermo Fisher Scientific). The flow cytometry antibodies were purchased from Thermo Fisher Scientific, Biolegend or BD Biosciences. Antibodies targeting TCR β (H57-597), B220 (RA3-6B2), CCR6 (29-2L17), CD3 ϵ (145-2C11), CD4 (RM4-5), CD5 (53-7.3), CD8 α (53-6.7), CD11b (M1/70), CD11c (N418), CD19 (eBio1D3), Ly6G (1A8-Ly6G), TCR $\gamma\delta$ (GL3), CD45 (30-F11), CD64 (X54-5/7.1), CD90.2 (30-H12), CD127 (A7R34), F4/80 (BM8), MHC-II (M5/114.15.2), NK1.1 (PK136), NKp46 (29A1.4), Xcr1 (ZET), CD172a (P84), CD132 (TUGm2), CD135 (A2F10), CD117 (ACK2), CD25 (PC61.5), $\alpha 4\beta 7$ (DATK32), KlrG1 (2F1/KLRG1), ST2 (DIH4), CXCR6 (SA051D1), OX40L (RM134L) were used for surface staining in mouse. Zbtb46 (U4-1374), Foxp3 (FJK-16S), Gata3 (L50-823), IL-17A (eBio 17B7), IL-22 (IL22JOP), IFN- γ (XMG1.2), Ki-67 (SolA15), ROR γt (B2D), PLZF (9E12), Irf4 (IRF4.3E4), Irf8 (V3GYWCH), COX-2 (EPR18377-106), anti-rabbit IgG (Poly 4064), rat IgG1 isotype control (R3-34) and T-bet (eBio4B10) were used for intracellular staining. Lineage markers for mouse are: CD3 ϵ , CD5, CD8 α , NK1.1, TCR $\gamma\delta$, Ly6G, CD11b, CD11c, B220, F4/80. All mouse antibodies were used at 1:200 dilution, except for CCR6, CD64, OX40L, Zbtb46, which were used at 1:100 dilution, and MHCII, Ki67, COX-2 used at 1:300 dilution. For human cells staining, antibodies against CD3 ϵ (UCHT1), CD11c (3.9), CD14 (TuK4), CD19 (HIB19), CD34 (581), CD45 (HI30), CD94 (DX22), CD117 (104D2), CD123 (6H6), CD127 (A019D5), Fc ϵ R1 (AER-37), CD64 (10.1), and MHCII (L243) were used for surface staining. Antibodies targeting ROR γt (Q21-559)

and Zbtb46 (U4-1374) were used for intracellular staining. Human ILC3s were gated as CD45⁺CD3⁻CD11c⁻CD14⁻CD19⁻CD34⁻CD94⁻CD123⁻FcεR1⁻CD127⁺CD117⁺ for sorting; macrophages were gated as CD45⁺CD3⁻CD19⁻CD64⁺MHCII⁺; cDCs were gated as CD45⁺CD3⁻CD19⁻CD64⁻CD11c^{hi}MHCII^{hi}; T cells were gated as CD45⁺CD3⁺CD4⁺, and B cells were gated as CD45⁺CD3⁻CD19⁺. For analysis, human ILC3s were gated as CD45⁺CD3⁻CD11c⁻CD14⁻CD19⁻CD34⁻CD94⁻CD123⁻FcεR1⁻CD127⁺CD117⁺RORγt⁺. All human antibodies were used at 1:200, except for RORγt and Zbtb46 which were used at 1:50.

For transcription factors, cells were first stained for surface markers, followed by fixation and permeabilization according to the manufacturer's protocol (FoxP3 staining buffer set from Thermo Fisher Scientific, cat# 00-5123-43). For cytokines, cells were stimulated in RPMI 1640 with 10% FBS, phorbol 12-myristate 13-acetate (PMA) 50 ng/ml (Sigma Aldrich), ionomycin 750 ng/ml (Sigma Aldrich) and brefeldin A 10 μg/ml (Sigma Aldrich) for 4 hours. All flow cytometry experiments were performed by a Fortessa flow cytometer and the FACS Diva software (BD Biosciences) and analyzed by FlowJo v. 10 software. FACS Aria II cell sorter (BD Biosciences) was used for cell sorting.

Single cell RNA-Sequencing and bulk RNA-Sequencing.

For single cell RNA-sequencing, two populations CD45⁺TCRβ⁺GFP⁺ (T cells) and CD45⁺TCRβ⁻GFP⁺ (non-T cells) were sorted from the large intestine of *RORγt-EGFP* mice and mixed equally at 1:1 ratio to enrich the non-T cell populations. Cells were pooled from 3 individual mice. scRNA-Seq libraries were generated using the 10X Genomics Chromium system with 3' version 3 chemistry. Libraries were sequenced on an Illumina NovaSeq instrument. Reads were processed by 10X's Cell Ranger version 3.1.0 using the mm10 reference genome, resulting in a filtered HDF5 file. scRNA-Seq data were further processed and analyzed using R version 3.6.3 (R Core Team 2020) and the Seurat package version 3.2.3⁵⁷. Specifically, Cell Ranger output was imported using the Read10X_h5 function. Seurat objects were created using only genes appearing in at least 3 cells. Cells were further filtered to exclude those with fewer than 600 genes detected, more than 5000 genes detected, or more than 10 percent mitochondrial reads. Read counts were then normalized using the NormalizeData function. The graph representing cells with similar expression patterns was generated with the FindNeighbors function using the 20 largest principal components. Cell clusters were generated using the Louvain algorithm implemented by the FindClusters function with resolution parameter equal to 0.4. Marker genes for each cluster were determined using the Wilcoxon test on the raw counts, implemented by the function FindAllMarkers, and including only positive marker genes with log fold changes greater than 0.25 and Bonferroni-corrected *p* values less than 0.01. Cluster names were determined by manual inspection of the lists of cluster marker genes. Dimensionality reduction by Uniform Manifold Approximation and Projection was performed using the RunUMAP function with the 20 largest principal components. All visualizations of scRNA-Seq data were generated using the Seurat package as well as ggplot2 version 3.3.3⁵⁸.

For bulk RNA-Sequencing, ILC3s (CD45^{dim}Lin⁻CD90.2^{hi}CD127⁺CCR6⁺) were sort-purified from the large intestine of *Zbtb46^{fl/fl}* and *Rorc^{Cre}Zbtb46^{fl/fl}* mice. Each group

includes 4 biological replicates. RNA sequencing libraries were generated by the Epigenomics Core at Weill Cornell Medicine using the Clontech SMARTer Ultra Low Input RNA Kit V4 (Clontech Laboratories). An Illumina NextSeq instrument was used to generate 50-bp single-end reads. Raw sequencing reads were demultiplexed with Illumina CASAVA (v.1.8.2). Adapters were trimmed from reads using FLEXBAR⁵⁹ and reads were aligned to the NCBI GRCm38/mm10 mouse genome using the STAR aligner (v.2.3.0)⁶⁰ with default settings. Reads per gene were counted using the featureCounts function of the Rsubread R package⁶¹. Differential expression was assessed using DESeq2⁶² version 1.26.0 with default parameters and with a false discovery rate of 0.1.

Progenitor cells transfer.

Bone marrow from both femur and tibia of hind legs of *Zbtb46^{GFP+}* was collected, lysed with TheraPEAK™ ACK lysis buffer (Lonza) to remove red blood cells, and then passed through 70 μ m cell strainer. Cell suspensions were directly stained with antibodies. Pre-DC was gated as CD45⁺Lin⁻CD127⁻MHCII⁻CD135⁺CD11c⁺CD117⁻CD16/32⁻GFP⁺; CHILP was gated as CD45⁺Lin⁻CD11c⁻CD127⁺CD135⁻ α 4 β 7⁺CD117⁺CD25⁻; Lineage markers included Ter119, B220, CD19, CD3, CD5, NK1.1, and Ly6G. *Rag2^{-/-}Il2rg^{-/-}* mice were used as the recipient mice. 20,000 cells of pre-DC or 800-1000 cells of CHILP were transferred into recipient mouse by intravenous injection. The intestine of recipient mice was analyzed 6 weeks later. For *Zbtb46*-GFP expression analysis in different progenitors from the bone marrow: ILCP was gated as Lin⁻CD45⁺CD127⁺ α 4 β 7⁺CD117⁺Flt3⁻PLZF⁺ROR γ ⁻. LTiP was gated as Lin⁻CD45⁺CD127⁺ α 4 β 7⁺CD117⁺Flt3⁻PLZF⁻ROR γ ⁺.

Quantitative PCR.

Sort-purified cells were lysed using Buffer RLT plus lysis buffer (QIAGEN). RNA was purified using RNeasy plus mini kits (QIAGEN) according to the manufacturer's instructions. First-strand cDNA was generated using Maxima First Strand cDNA synthesis kit according to the protocol provided by the manufacturer (Thermo Fisher Scientific, cat# K1642). Power SYBR green PCR Master Mix (Thermo Fisher Scientific, cat# 4367660) was used for Real-time qPCR with ABI7500 (Applied Biosystems). Gene expression was normalized to internal controls *Hprt* or *Actb* for mouse samples or *ACTB* for human samples.

C. rodentium infection.

C. rodentium were cultured in LB broth overnight at 37°C with constant shaking and 1-2x10⁹ bacteria were used to infect mice by oral gavage. Fecal pellets were collected at day 8 or day 10 to count the fecal CFU of *C. rodentium*. Mice were sacrificed at 13-16 days post infection for analysis. The colon length was measured, and distal colon was used for histological analysis.

Antibiotics administration and ex-GF mice generation.

Zbtb46^{GFP+} mice were used. A cocktail of antibiotics (0.25 mg/ml vancomycin, 0.5 mg/ml ampicillin, 0.5 mg/ml neomycin, 0.5 mg/ml gentamycin, and 0.5 mg/ml metronidazole) was

continuously administered through drinking water for 2 weeks. To generate ex-GF mice, cecum contents from C57BL/6J mice were collected and resuspended in PBS supplemented with 10% glycerol. 200 μ l fresh fecal suspension was administered to recipient germ-free mice by oral gavage. Inoculated animals were subsequently maintained in a sterile isocage with autoclaved food and water for two weeks before analyzing.

Neutralization antibody in vivo blockade.

Anti-OX40L (clone RM134L) antibody was purchased from BioXCell and administered intraperitoneally twice every week at a dose of 500 μ g/mouse for two weeks. IgG (Sigma-Aldrich, I4131) was used as a control.

Ex vivo cytokine stimulation.

CCR6⁺ ILC3s were sort-purified from the small intestine of C57BL/6 mice and stimulated with 10 ng/ml IL-23, 10 ng/ml IL-1 β , or 50 ng/ml TL1A for 4 hours.

ATAC-seq analysis.

Four CCR6⁺ ILC3 ATAC-seq data (GSM3208782, GSM3208785, GSM3208763, GSM3208764) from a previous study²⁷ were downloaded from the SRA database. The raw data were processed with the ENCODE ATAC-seq pipeline (<https://github.com/ENCODE-DCC/atac-seq-pipeline>). The reads were trimmed, filtered and aligned against NCBI GRCm38/mm10 mouse genome using Bowtie2⁶³. PCR duplicates and reads mapped to the mitochondrial chromosome or repeated regions were removed. The Integrative Genomics Viewer was used for data visualization⁶⁴.

Histological staining.

Large intestinal swiss rolls were fixed in 4% paraformaldehyde and embedded in paraffin. 5- μ m sections were stained with hematoxylin and eosin. Images were taken using a Nikon Eclipse Ti microscope and NIS-Elements 4.30.02 software (Nikon).


Statistical analysis.

All statistical analyses were performed by Graph Pad Prism V9 software. Paired or unpaired two-tailed Student's *t*-test, Mann-Whitney test (for data set not normally distributed), or One-way ANOVA with 95% confidence interval followed by Dunnett's multiple comparison, was used to determine the *P* value of each data set generated from mice. One-way ANOVA Kruskal-Wallis test with Dunn's multiple comparisons, or two-tailed Wilcoxon test was used to analyze data sets generated from humans. *P* values less than 0.05 were considered as significant. Simple linear regression was used to determine the *P* value of correlation. Log-rank (Mantel-Cox) test was used to determine the *P* value of survival rate.

Data availability.


All data necessary to understand and evaluate the conclusions of this paper are provided. Bulk RNA-Seq data have been deposited in the Gene Expression Omnibus database under the accession number GSE181865, scRNA-Seq data are under the accession number GSE181864.

Extended Data



Extended Data Figure 1. Gating of immune cells from the large intestine of mice.
a. Cells were isolated from the large intestine lamina propria of $ROR\gamma t-EGFP$ reporter mice. Two populations, $TCR\beta^+$ cells and $TCR\beta^-$ cells, of $ROR\gamma t^+$ immune cells were sorted separately and equally mixed at a 1:1 ratio, permitting enrichment of non-T lymphocyte populations. **b.** Gating strategy for different immune cells with surface markers. Lineage markers included: CD3, CD5, NK1.1, $TCR\gamma\delta$, Ly6G. B cells


were gated as CD45⁺CD19⁺; Macrophages (Mac) were gated as CD45⁺CD64⁺MHCII⁺; cDCs were gated as CD45⁺Lin⁻CD64⁻CD11^{hi}MHCII^{hi}. CD4⁺ T cells were gated as CD45⁺Lin⁺CD4⁺; ILC2s were gated as CD45⁺Lin⁻CD64⁻CD11c⁻CD127⁺CD90⁺KLRG1⁺; ILC3s were gated as CD45^{dim}Lin⁻CD64⁻CD11c⁻CD127⁺CD90^{hi}KLRG1⁻; ILC3s were further gated as CCR6⁺, NKp46⁺ or DN subset. **c.** Gating strategy for different immune cells with transcription factors. Lineage 1: CD3, CD5, NK1.1, TCR $\gamma\delta$, Ly6G. Lineage 2: F4/80 and B220. cDCs were gated as CD45⁺Lin⁻CD11^{hi}MHCII^{hi}; Th17 cells were gated as CD45⁺Lin⁺CD4⁺FoxP3⁻ROR γ t⁺; ILC3s were gated as CD45⁺Lin⁻CD11c⁻CD127⁺CD90⁺ROR γ t⁺, and further gated as CCR6⁺, T-bet⁺, or DN; ILC2s were gated as CD45⁺Lin⁻CD11c⁻CD127⁺CD90⁺ROR γ t⁻T-bet⁻.



Extended Data Figure 2. ROR γ t expression among ILCs and cDCs.

- a.** Representative flow cytometry plots and quantifications of ROR γ t⁺ cells in cDCs and ILCs in the large intestine (LI) (n = 3 mice) or spleen of C57BL/6 mice by protein staining (n = 4 mice). ILCs were gated as CD45⁺Lin⁻CD11c⁻CD127⁺CD90.2⁺. **b.** Representative flow cytometry plots and quantifications of ROR γ t-EGFP⁺ cells in cDCs and ILCs in *ROR γ t-EGFP* reporter mice (n = 3 mice). **c.** Representative flow cytometry plots and quantifications of YFP⁺ cells in cDCs and ILCs in *Rorc^{Cre}ROSA26^{sl-EYFP}* fate mapping mice (n = 3 mice). **d.** Representative flow cytometry plots of ROR γ t-EGFP⁺ cells in endothelial cells in *ROR γ t-EGFP*


EGFP reporter mice. Data are representative of two or three independent experiments and shown as the means \pm S.E.M in **a-d**.



Extended Data Figure 3. Zbtb46 is significantly enriched in CCR6⁺ LTi-like ILC3s from the intestine.

a. Quantifications of frequencies of Zbtb46-GFP⁺ cells in indicated ILC3 subsets in the large intestine (LI) or small intestine (SI) of *Zbtb46*^{GFP/+} mice (n = 4 mice for both LI and SI). **b-d.** Unbiased gating for Zbtb46-GFP⁺ cells from the large intestine of *Zbtb46*^{GFP/+} mice. **c.** Quantification of the frequency of Zbtb46-GFP⁺ cDCs or ILC3s in total CD45⁺


immune cells from the large intestine of *Zbtb46^{GFP/+}* mice (n = 4 mice). **d.** Quantification of the frequency of Zbtb46-GFP⁺ ILC3 subsets from the large intestine of *Zbtb46^{GFP/+}* mice (n = 4 mice). **e.** Representative flow plots and quantifications of frequencies of *Zbtb46^{Cre}* fate-mapped cells in indicated ILC3 subsets in the large intestine (LI) or small intestine (SI) of *Zbtb46^{Cre}ROSA26^{sl-EYFP}* mice (n = 4 for both LI and SI). **f.** Representative flow histograms and quantifications of Zbtb46 MFI in indicated ILC3 subsets from the large intestine (LI) or small intestine (SI) of C57BL/6 or *Zbtb46^{GFP/GFP}* mice (n = 3 for both LI and SI). The dash line indicates Zbtb46 MFI in CCR6⁺ ILC3s from *Zbtb46^{GFP/GFP}*. Data are representative of two or three independent experiments and shown as the means ± S.E.M.. Statistics are calculated by One-way ANOVA with Dunnett's multiple comparisons in **a**, **d**, **e**, and **f**, two-tailed unpaired Student's *t*-test in **c**.



Extended Data Figure 4. Zbtb46 is expressed by ILC3s in mucosal and lymphoid tissues.

a. Representative flow plots of Zbtb46-GFP $^+$ cells in $\gamma\delta$ T cells in the large intestine of C57BL/6 or $Zbtb46^{GFP/+}$ mice (n = 4 mice). **b.** Representative flow cytometry histogram and quantification of Zbtb46 MFI in indicated T cell subsets from the large intestine of C57BL/6 or $Zbtb46^{GFP/GFP}$ mice (n = 3 mice). The dash line indicates Zbtb46 MFI in CD4 $^+$ T cells from $Zbtb46^{GFP/GFP}$. **c.** Quantification of Zbtb46-GFP $^+$ cell frequencies of indicated cells in the small intestine (SI), mesenteric lymph nodes (mLN), periphery lymph nodes (pLN), Spleen, Lung, Fat, Skin, and salivary gland of $Zbtb46^{GFP/+}$ mice (n = 4 mice for

all tissues). **d.** Quantification of Zbtb46-GFP⁺ cell frequencies of ILC3 subsets in the large intestine of *Zbtb46*^{GFP/+} female or male mice (n = 8 or 5 mice per group for all subsets). Data are representative of two independent experiments **a-c**, and data are pooled from 2 individual experiments in **d**. Data are shown as the means ± S.E.M. in **b-d**, means ± S.D. in **a**. Statistics are calculated by One-way ANOVA with Dunnett's multiple comparisons in **c** and by two-tailed unpaired Student's *t*-test in **d**.




Extended Data Figure 5. Gating strategy for different immune cells in human intestine.

a. Lineage markers included: CD19, CD94, CD14, CD123, FcεR1a, CD34. B cells were gated as CD45⁺CD19⁺CD3⁻; Macrophages (Mac) were gated as CD45⁺CD19⁻CD3⁻CD64⁺MHCII⁺; cDCs were gated as CD45⁺CD19⁻CD3⁻CD64⁻CD11^{hi}MHCII^{hi}. CD4⁺ T cells were gated as CD45⁺CD3⁺CD4⁺; ILC3s were gated as CD45⁺Lin⁻CD3⁻CD127⁺CD117⁺. **b,c.** Representative flow cytometry histogram of ZBTB46 staining and quantification of ZBTB46 MFI in indicated cells from human tonsils (n = 4 individual donors per group). FMO: full staining minus one; Isotype: Isotype control. Data are representative of two independent experiments in **b,c**, and shown as the means ± S.E.M. Statistics are calculated by One-way ANOVA with Dunnett's multiple comparisons.

CHILP were gated as (Ter119, B220, CD19, NK1.1, CD3, CD5, CD11b, CD11c, Ly6G)⁻CD45⁺CD127⁺α4β7⁺Flt3⁻CD25⁻CD117⁺. **c.** Representative flow plots of recipient mice injected with indicated progenitor cells. γc staining was used to differentiate the host-derived and recipient-derived ILCs. **d.** Gating strategies for progenitors and LTi cells from the fetal tissue. **e.** RORγt (RORE) motif analysis of the *Zbtb46* locus in ATAC-seq data from CCR6⁺ ILC3s. **f.** *Zbtb46* expression relative to *Hprt* in sort purified CCR6⁺ ILC3s with or without exposure to the RORγt inhibitor GSK805 (n = 11 mice). **g.** Quantification of Zbtb46 MFI in CCR6⁺ or CCR6⁻ ILC3s from the large intestine of indicated mice (n = 6 or 5 mice per group for both subsets). **h.** Quantification of cell numbers of Zbtb46-GFP⁺ cells in indicated ILC3 subsets from the large intestine of water or ABX-treated *Zbtb46*^{GFP/+} mice (n = 5 mice for all subsets). **i.** Correlation analysis of ZBTB46 expression and disease scores in Ulcerative colitis patients. Data are pooled from three or two individual experiments in **f** and **g**, data are representative of two independent experiments in **h**. Data are shown as means ± S.E.M in **g** and **h**. Statistics are calculated by two-tailed paired Student's *t*-test in **f**, two-tailed unpaired Student's *t*-test in **g** and **h**, and the correlation is determined by simple linear regression in **i**.


of indicated mice (n = 5 mice per group). **f.** Quantification of the frequencies of IL-22⁺ ILC3s in indicated mice (n = 8 or 7 mice per group). **g.** Quantification of the frequencies of IL-17A⁺ ILC3s in indicated mice (n = 4 or 5 mice per group). **h.** Quantification of the cell numbers of IL-22⁺ ILC3s in indicated mice (n = 4 mice per group). **i.** Quantification of the cell numbers of IL-17A⁺ ILC3s (n = 4 or 5 mice per group) in indicated mice. **j,k.** Representative flow plots and quantification of the frequencies of MHCII⁺ CCR6⁺ ILC3s in the large intestine of indicated mice (n = 5 mice per group). **l.** Quantification of MHCII MFI in CCR6⁺ ILC3s in indicated mice (n = 5 mice per group). **m.** Quantification of mLN weight and the numbers of Peyer's patches in indicated mice (n = 9 mice per group). **n.** Go pathway analysis of the upregulated genes in the *Rorc*^{Cre}*Zbtb46*^{f/f} mice compared to *Zbtb46*^{f/f} mice. **o.** Quantification of the frequencies of COX-2⁺ (n = 4 or 5 mice per group) or IL-6 MFI (n = 4 or 5 mice per group) in ILC3s in the large intestine of indicated mice. **p.** Zbtb46 motif analysis of the *Tnfrsf4* and *Ptgs2* loci in ATAC-seq data from CCR6⁺ ILC3s. Data are representative of three independent experiments in **a, b, e, g-l, o.** Data are pooled from two independent experiments in **c, d, f, m.** Data are shown as the means ± S.E.M. Statistics are calculated by two-tailed unpaired Student's *t*-test.



Extended Data Figure 8. Zbtb46 regulates ILC3s in a cell-intrinsic manner.

a. Schematic of mixed bone marrow (BM) chimera. The BM of CD45.2 *Zbtb46*^{GFP/GFP} and CD45.1 C57BL/6 mice was equally mixed and transferred into *Rag2*^{-/-}*Il2rg*^{-/-} recipient mice. Mice were analyzed 6-8 weeks after transplantation. **b,c.** Representative flow plots of the composition of ILC3s or ILC2s, and quantification of the ratio of CD45.2 to CD45.1 cells in ILC3s or ILC2s in the large intestine of recipient mice (n = 4 mice). **d.** Representative flow plots of the composition of CD4⁺ T cells in non-transplanted (control) or BM chimera mice. **e.** Quantification of the frequencies of indicated CD4⁺ T cells in the

large intestine of BM chimera mice (n = 5 mice). **f.** Quantification of the frequencies of indicated ROR γ ⁺ CD4⁺ T cells in the large intestine of BM chimera mice (n = 5 mice). **g.** Quantification of the frequencies of IL-17A⁺ CD4⁺ T cells in indicated congenic T cells of BM chimera mice (n = 4 mice). **h.** Representative flow cytometry histograms of Zbtb46 in CD4⁺ T cells in the large intestine of indicated mice. **i.** Quantification of the frequencies of Th17 cells in indicated mice (n = 6 or 3 mice per group). **j.** Quantification of the frequencies of IL-17A⁺ CD4⁺ T cells in indicated mice (n = 6 or 3 mice per group). **k-s.** Mice were orally infected with *C. rodentium* for two weeks prior to analysis. **k.** Representative flow cytometry histograms of Zbtb46 in cDCs and different T cell subsets. **l.** Quantification of the frequencies of ILC3 subsets in the large intestine of indicated mice (n = 5 or 4 mice per group for both subsets). **m,n.** Quantification of the frequencies of Ki67⁺ ILC3 (n = 4 or 5 mice per group) and Ki67⁺ CCR6⁺ ILC3s (n = 4 or 5 mice per group) in the large intestine of indicated mice. **o-r.** Quantification of the frequencies of IL-22⁺ (n = 5 mice per group), GMCSF⁺ (n = 4 or 5 mice per group), IL-17A⁺ (n = 4 or 5 mice per group), and IL-17F⁺ (n = 4 or 5 mice per group) ILC3s in the large intestine of indicated mice. **s.** Quantification of the frequencies of IFN γ ⁺ CD4⁺ T cells in the large intestine of indicated mice (n = 6 or 5 mice per group). Data are representative of two or three independent experiments in **b-s**. Data are shown as the means \pm S.E.M. Statistics are calculated by two-tailed unpaired Student's *t*-test.



Extended Data Figure 9. *Zbtb46*⁺ ILC3s are a dominant source of tissue protective IL-22.

a. UMAPs show the expression of *Ii22* or *Zbtb46* in all clusters of $ROR\gamma t^+$ immune cells from the large intestine of $ROR\gamma t^{EGFP}$ mice. The dash circle indicates IL-22⁺ ILC3s.
b. Representative flow plot of IL-22 and *Zbtb46* expression in the large intestine of *Zbtb46*^{GFP/+} mice. **c.** Quantification of CCR6⁺ ILC3s in total IL22-YFP⁺ cells from the large intestine of *Ii22*^{Cre}*ROSA26*^{sl-YFP} mice (n = 4 mice). **d.** Representative flow plots presenting unbiased gating for IL22-YFP⁺ cells in the large intestine of *Ii22*^{Cre}*ROSA26*^{sl-EYFP} fate-mapping mice. Lineage 1: CD3, CD5, NK1.1, TCRγδ, Ly6G. Lineage 2: F4/80 and B220.

e. Representative flow plots and quantification of CCR6⁺ cells in the large intestine of indicated mice. Cells were gated from Lineage⁻CD90.2⁺CD127⁺ cells (n = 4 or 5 mice per group). **f.** Quantification of the frequencies of cDCs in the large intestine of indicated mice (n = 5 mice per group). **g.** Quantification of the frequencies of RORγt⁺ CD4⁺ T Cells in the large intestine of indicated mice (n = 9 or 8 mice per group). **h, i.** Representative flow plots and quantification of Th17 or IL-17A⁺ CD4⁺ T cells in the large intestine of indicated mice (n = 5 mice per group). **j,k.** Representative flow plots and quantification of the frequencies of RORγt⁺ γδ T cells in the large intestine of indicated mice (n = 9 or 8 mice per group). **l.** Representative flow plots and quantification of the frequencies of IL-22⁺ cells in the large intestine of indicated mice (n = 4 or 5 mice per group). Cells were gated from Lineage⁻CD90.2⁺CD127⁺ cells. **m.** Quantification of the frequencies IL-22⁺ ILC3s in the large intestine of indicated mice (n = 4 or 5 mice per group). Cells were gated from Lineage⁻CD90.2⁺CD127⁺RORγt⁺ ILC3s. **n.** Quantification of the frequencies IL-22⁺ CD4⁺ T cells in the large intestine of indicated mice (n = 4 or 5 mice per group). **o-q.** Mice were orally infected with *C. rodentium* for two weeks prior to analysis. **o.** Quantification of the frequencies of CCR6⁺ ILCs in the large intestine of indicated mice (n = 5 or 3 mice per group). Cells were gated from Lineage⁻CD90.2⁺CD127⁺ cells. **p.** Quantification of survival rate of indicated mice following *C. rodentium* infection (n = 21 or 23 mice per group). **q.** Quantification of the frequencies of RORγt⁺ γδ T cells out of total CD45⁺ cells in the large intestine of indicated mice (n = 10 or 6 mice per group). Data are representative of two independent experiments in **b-d**, and three independent experiments in **e,f, h, i, l-o**. Data are pooled from two independent experiments in **g, k**, and **q**. Data are pooled from four independent experiments in **p**. Data are shown as the means ± S.E.M. in **c, e, f, g, i, k-o, q**, and means ± S.D. in **h**. Statistics are calculated by two-tailed unpaired Student's *t*-test in **e-g, i, k-o, q**, and by Log-rank (Mantel-Cox) test in **p**.



Extended Data Figure 10. Regulation and function of Zbtb46⁺ ILC3s.

a. Representative flow cytometry histogram of ROR γ t expression in CD4⁺ ILCs from the large intestine of indicated mice. Cells were gated from Lineage⁻CD90.2⁺CD127⁺CD4⁺ cells. **b,c.** Representative flow cytometry histogram of Zbtb46 expression and quantification of Zbtb46 MFI in CD4⁺ ILCs from the large intestine of indicated mice (n = 4 or 5 mice per group). Cells were gated from Lineage⁻CD90.2⁺CD127⁺CD4⁺ cells. **d.** Representative flow cytometry histogram of ROR γ t expression in CCR6⁺ ILC3s from the large intestine of indicated mice. Cells were gated from Lineage⁻CD90.2⁺CD127⁺ROR γ t⁺CCR6⁺ cells.

e,f. Representative flow cytometry histogram of Zbtb46 expression and quantification of Zbtb46 MFI in CCR6⁺ ILC3s from the large intestine of indicated mice (n = 4 or 5 mice per group). Cells were gated from Lineage⁻CD90.2⁺CD127⁺RORγt⁺CCR6⁺ cells. Data are representative of two independent experiments in **a-f**. Data are shown as the means ± S.E.M. Statistics are calculated by two-tailed unpaired Student's *t*-test. **g.** Zbtb46 defines and regulates group 3 innate lymphoid cells that protect the intestine.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank members of the Sonnenberg Laboratory for discussions and critical reading of the manuscript. Research in the Sonnenberg Laboratory is supported by the National Institutes of Health (R01AI143842, R01AI123368, R01AI145989, U01AI095608, R21CA249274, R01AI162936, and R01CA274534), an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, the Meyer Cancer Center Collaborative Research Initiative, The Dalton Family Foundation, and Linda and Glenn Greenberg. W.Z. is supported by fellowship from the Crohn's and Colitis Foundation (831404). L.Z. is supported by fellowship from the Crohn's and Colitis Foundation (608975). G.F.S. is a CRI Lloyd J. Old STAR. We would like to thank the Epigenomics Cores of Weill Cornell Medicine, Gregory Putzel, and all contributing members of the JRI IBD Live Cell Bank, which is supported by the JRI, Jill Roberts Center for IBD, Cure for IBD, the Rosanne H. Silbermann Foundation, the Sanders Family and Weill Cornell Medicine Division of Pediatric Gastroenterology and Nutrition.

Appendix

JRI Live Cell Bank consortium members:

David Artis³, Randy Longman³, Gregory Sonnenberg³, Ellen Scherl³, Robbyn Sockolow³, Dana Lukin³, Robert Battat³, Thomas Ciecierrega³, Aliza Solomon³, Elaine Barfield³, Kimberley Chien³, Johanna Ferreira³, Jasmin Williams³, Shaira Khan³, Peik Sean Chong³, Samah Mozumder³, Lance Chou³, Wenqing Zhou³, Mohd Ahmed³, Connie Zhong³, Ann Joseph³, Sanchita Kashyap³, Joseph Gladstone³, and Samantha Jensen³.

References

1. Eberl G et al. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. *Nat Immunol* 5, 64–73, doi:10.1038/ni1022 (2004). [PubMed: 14691482]
2. Eberl G & Littman DR Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells. *Science* 305, 248–251, doi:10.1126/science.1096472 (2004). [PubMed: 15247480]
3. Ivanov II et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* 126, 1121–1133, doi:10.1016/j.cell.2006.07.035 (2006). [PubMed: 16990136]
4. Ivanov II, Zhou L & Littman DR Transcriptional regulation of Th17 cell differentiation. *Semin Immunol* 19, 409–417, doi:10.1016/j.smim.2007.10.011 (2007). [PubMed: 18053739]
5. Luci C et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. *Nat Immunol* 10, 75–82, doi:10.1038/ni.1681 (2009). [PubMed: 19029904]
6. Zhou L & Littman DR Transcriptional regulatory networks in Th17 cell differentiation. *Curr Opin Immunol* 21, 146–152, doi:10.1016/j.coi.2009.03.001 (2009). [PubMed: 19328669]

7. Sanos SL et al. ROR γ and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46⁺ cells. *Nat Immunol* 10, 83–91, doi:10.1038/ni.1684 (2009). [PubMed: 19029903]
8. Cella M et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. *Nature* 457, 722–725, doi:10.1038/nature07537 (2009). [PubMed: 18978771]
9. Martin B, Hirota K, Cua DJ, Stockinger B & Veldhoen M Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. *Immunity* 31, 321–330, doi:10.1016/j.immuni.2009.06.020 (2009). [PubMed: 19682928]
10. Sutton CE et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. *Immunity* 31, 331–341, doi:10.1016/j.immuni.2009.08.001 (2009). [PubMed: 19682929]
11. Buonocore S et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. *Nature* 464, 1371–1375, doi:10.1038/nature08949 (2010). [PubMed: 20393462]
12. Sawa S et al. Lineage relationship analysis of ROR γ ⁺ innate lymphoid cells. *Science* 330, 665–669, doi:10.1126/science.1194597 (2010). [PubMed: 20929731]
13. Ohnmacht C et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through ROR γ ⁺ T cells. *Science* 349, 989–993, doi:10.1126/science.aac4263 (2015). [PubMed: 26160380]
14. Sefik E et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of ROR γ ⁺ regulatory T cells. *Science* 349, 993–997, doi:10.1126/science.aaa9420 (2015). [PubMed: 26272906]
15. Eberl G ROR γ , a multitask nuclear receptor at mucosal surfaces. *Mucosal Immunol* 10, 27–34, doi:10.1038/mi.2016.86 (2017). [PubMed: 27706126]
16. Satpathy AT et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. *J Exp Med* 209, 1135–1152, doi:10.1084/jem.20120030 (2012). [PubMed: 22615127]
17. Meredith MM et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. *J Exp Med* 209, 1153–1165, doi:10.1084/jem.20112675 (2012). [PubMed: 22615130]
18. Satpathy AT, Wu X, Albring JC & Murphy KM Re(de)fining the dendritic cell lineage. *Nat Immunol* 13, 1145–1154, doi:10.1038/ni.2467 (2012). [PubMed: 23160217]
19. Merad M, Sathe P, Helft J, Miller J & Mortha A The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu Rev Immunol* 31, 563–604, doi:10.1146/annurev-immunol-020711-074950 (2013). [PubMed: 23516985]
20. Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M & Reis E Sousa C Dendritic Cells Revisited. *Annu Rev Immunol* 39, 131–166, doi:10.1146/annurev-immunol-061020-053707 (2021). [PubMed: 33481643]
21. Hepworth MR et al. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells. *Science* 348, 1031–1035, doi:10.1126/science.aaa4812 (2015). [PubMed: 25908663]
22. Zhou L et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. *Nature* 568, 405–+, doi:10.1038/s41586-019-1082-x (2019). [PubMed: 30944470]
23. Teng F et al. A circadian clock is essential for homeostasis of group 3 innate lymphoid cells in the gut. *Sci Immunol* 4, doi:10.1126/sciimmunol.aax1215 (2019).
24. Fujino S et al. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 52, 65–70, doi:10.1136/gut.52.1.65 (2003). [PubMed: 12477762]
25. Brown CC et al. Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity. *Cell* 179, 846–863.e824, doi:10.1016/j.cell.2019.09.035 (2019). [PubMed: 31668803]
26. Schraml BU et al. Genetic tracing via DNDR-1 expression history defines dendritic cells as a hematopoietic lineage. *Cell* 154, 843–858, doi:10.1016/j.cell.2013.07.014 (2013). [PubMed: 23953115]
27. Pokrovskii M et al. Characterization of Transcriptional Regulatory Networks that Promote and Restrict Identities and Functions of Intestinal Innate Lymphoid Cells. *Immunity* 51, 185–197.e186, doi:10.1016/j.immuni.2019.06.001 (2019). [PubMed: 31278058]

28. Britanova L & Diefenbach A Interplay of innate lymphoid cells and the microbiota. *Immunol Rev* 279, 36–51, doi:10.1111/imr.12580 (2017). [PubMed: 28856740]
29. Chen WY et al. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. *Oncogene* 36, 6213–6224, doi:10.1038/ncr.2017.226 (2017). [PubMed: 28692046]
30. Kugathasan S et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. *Nat Genet* 40, 1211–1215, doi:10.1038/ng.203 (2008). [PubMed: 18758464]
31. Meredith MM et al. Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady state. *J Exp Med* 209, 1583–1593, doi:10.1084/jem.20121003 (2012). [PubMed: 22851594]
32. Castellanos JG et al. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis. *Immunity* 49, 1077–1089.e1075, doi:10.1016/j.immuni.2018.10.014 (2018). [PubMed: 30552020]
33. Gajdasik DW et al. Th1 responses in vivo require cell-specific provision of OX40L dictated by environmental cues. *Nat Commun* 11, 3421, doi:10.1038/s41467-020-17293-3 (2020). [PubMed: 32647184]
34. Yao C et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. *Nat Med* 15, 633–640, doi:10.1038/nm.1968 (2009). [PubMed: 19465928]
35. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A & Sallusto F Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. *Eur J Immunol* 39, 1301–1312, doi:10.1002/eji.200838969 (2009). [PubMed: 19384872]
36. Vély F et al. Evidence of innate lymphoid cell redundancy in humans. *Nat Immunol* 17, 1291–1299, doi:10.1038/ni.3553 (2016). [PubMed: 27618553]
37. Rankin LC et al. Complementarity and redundancy of IL-22-producing innate lymphoid cells. *Nat Immunol* 17, 179–186, doi:10.1038/ni.3332 (2016). [PubMed: 26595889]
38. Song C et al. Unique and redundant functions of NKp46(+) ILC3s in models of intestinal inflammation. *Journal of Experimental Medicine* 212, 1869–1882, doi:10.1084/jem.20151403 (2015). [PubMed: 26458769]
39. Zheng Y et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nature Medicine* 14, 282–289, doi:10.1038/nm1720 (2008).
40. Sonnenberg G, Monticelli L, Elloso M, Fouser L & Artis D CD4(+) Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut. *Immunity* 34, 122–134, doi:10.1016/j.immuni.2010.12.009 (2011). [PubMed: 21194981]
41. Ota N et al. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with *Citrobacter rodentium*. *Nat Immunol* 12, 941–948, doi:10.1038/ni.2089 (2011). [PubMed: 21874025]
42. Dudakov JA, Hanash AM & van den Brink MR Interleukin-22: immunobiology and pathology. *Annu Rev Immunol* 33, 747–785, doi:10.1146/annurev-immunol-032414-112123 (2015). [PubMed: 25706098]
43. Basu R et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. *Immunity* 37, 1061–1075, doi:10.1016/j.immuni.2012.08.024 (2012). [PubMed: 23200827]
44. Leppkes M et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. *Gastroenterology* 136, 257–267, doi:10.1053/j.gastro.2008.10.018 (2009). [PubMed: 18992745]
45. Bernink JH et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. *Nat Immunol* 14, 221–229, doi:10.1038/ni.2534 (2013). [PubMed: 23334791]
46. Wang Y et al. ZBTB46 is a shear-sensitive transcription factor inhibiting endothelial cell proliferation via gene expression regulation of cell cycle proteins. *Lab Invest* 99, 305–318, doi:10.1038/s41374-018-0060-5 (2019). [PubMed: 29884909]
47. Loschko J et al. Inducible targeting of cDCs and their subsets in vivo. *J Immunol Methods* 434, 32–38, doi:10.1016/j.jim.2016.04.004 (2016). [PubMed: 27073171]

48. Caton ML, Smith-Raska MR & Reizis B Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. *J Exp Med* 204, 1653–1664, doi:10.1084/jem.20062648 (2007). [PubMed: 17591855]
49. Ahlfors H et al. IL-22 fate reporter reveals origin and control of IL-22 production in homeostasis and infection. *J Immunol* 193, 4602–4613, doi:10.4049/jimmunol.1401244 (2014). [PubMed: 25261485]
50. Srinivas S et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev Biol* 1, 4, doi:10.1186/1471-213x-1-4 (2001). [PubMed: 11299042]
51. Choi GB et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. *Science* 351, 933–939, doi:10.1126/science.aad0314 (2016). [PubMed: 26822608]
52. Finotto S et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. *Science* 295, 336–338, doi:10.1126/science.1065544 (2002). [PubMed: 11786643]
53. Kühn R, Löhler J, Rennick D, Rajewsky K & Müller W Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75, 263–274, doi:10.1016/0092-8674(93)80068-p (1993). [PubMed: 8402911]
54. Lee PP et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. *Immunity* 15, 763–774, doi:10.1016/s1074-7613(01)00227-8 (2001). [PubMed: 11728338]
55. Loschko J et al. Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. *J Exp Med* 213, 517–534, doi:10.1084/jem.20160062 (2016). [PubMed: 27001748]
56. Schlenner SM et al. Fate mapping reveals separate origins of T cells and myeloid lineages in the thymus. *Immunity* 32, 426–436, doi:10.1016/j.immuni.2010.03.005 (2010). [PubMed: 20303297]
57. Butler A, Hoffman P, Smibert P, Papalexi E & Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 36, 411–420, doi:10.1038/nbt.4096 (2018). [PubMed: 29608179]
58. Hadley W *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlag New York, 2016).
59. Dodt M, Roehr JT, Ahmed R & Dieterich C FLEXBAR-Flexible Barcode and Adapter Processing for Next-Generation Sequencing Platforms. *Biology (Basel)* 1, 895–905, doi:10.3390/biology1030895 (2012). [PubMed: 24832523]
60. Dobin A et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21, doi:10.1093/bioinformatics/bts635 (2013). [PubMed: 23104886]
61. Liao Y, Smyth GK & Shi W The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res* 47, e47, doi:10.1093/nar/gkz114 (2019). [PubMed: 30783653]
62. Love MI, Huber W & Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15, 550, doi:10.1186/s13059-014-0550-8 (2014). [PubMed: 25516281]
63. Langmead B & Salzberg SL Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9, 357–359, doi:10.1038/nmeth.1923 (2012). [PubMed: 22388286]
64. Robinson JT, Thorvaldsdóttir H, Wenger AM, Zehir A & Mesirov JP Variant Review with the Integrative Genomics Viewer. *Cancer Res* 77, e31–e34, doi:10.1158/0008-5472.CAN-17-0337 (2017). [PubMed: 29092934]




Figure 1. A single cell atlas of $ROR\gamma^t$ immune cells identifies *Zbtb46* expression in ILC3s.
a. scRNA-seq UMAP projection of $ROR\gamma^t$ immune cells from the large intestine of *ROR\gamma^t*^{EGFP} mice. **b.** Violin plots of selected genes. **c.** Dot plot of selected gene. **d.** Dot plot of cDC markers. **e.** *Zbtb46* mRNA relative to *Hprt* in indicated cells from the large intestine of C57BL/6 mice ($n = 5$ mice for cDCs or 6 for all others). **f, g.** Histogram of GFP (**f**), GFP⁺ cell frequency (**g**) ($n = 4$ mice), of indicated cells in the large intestine of *Zbtb46*^{GFP/+} mice. **h.** Flow cytometry plots of indicated ILC3 subsets in the large intestine of *Zbtb46*^{GFP/+} mice ($n = 4$ mice). **i.** Quantification of YFP⁺ cells of indicated cells in

the large intestine of *Zbtb46^{Cre}ROSA26^{sl-EYFP}* mice (n = 4 mice). **j,k**. Flow cytometry histogram (**j**) of Zbtb46 staining and quantification of geometric mean fluorescence intensity (MFI) in indicated cells (**k**) (n = 3 mice). The dash line indicates Zbtb46 MFI in CCR6⁺ ILC3s from *Zbtb46^{GFP/GFP}* mice. **l**. *ZBTB46* mRNA relative to *ACTB* in indicated cells sorted from the non-inflamed human intestine (n = 5 individual donors for ILC3s or 6 for all others). **m**. Quantification of *ZBTB46* MFI in indicated cells from the healthy human intestine (n = 19 individual donors). MFI in CD4⁺ T cells was normalized to 0. Data in **e** are pooled from two independent experiments; data in **f, g, h, i, j, and k** are representative of two or three independent experiments. Data are shown as the means ± S.E.M in **e, g, i, k, l, m**, and means ± S.D. in **h**. Statistics are calculated by one-way ANOVA with Dunnett's multiple comparisons in **e, g, i, and k**; one-way ANOVA Kruskal-Wallis test with Dunn's multiple comparisons in **l, and m**.




Figure 2. *Zbtb46*⁺ ILC3s are distinct from cDCs and modulated by ROR γ t, microbes, and cytokines.

a. Histogram of indicated markers. FMO: full staining minus one. **b.** Quantification of YFP⁺ cells in the large intestine of indicated fate-mapping mice (n = 3 or 4 mice). **c.** Representative histograms for indicated cells from the bone marrow. **d.** ILC3 frequency (left, n = 4 or 6 mice) and *Zbtb46*-GFP⁺ ILC3s (right, n = 4 or 6 mice) from the intestine of *Rag2*^{-/-}*Il2rg*^{-/-} recipient mice. **e, f.** Representative plots and quantification from fetal gut of *Zbtb46*^{GFP+} mouse embryos at E14.5 (each dot represents 2 pooled embryos, n = 8

embryos). **g.** Quantification of frequencies of cells from fetal liver of *Zbtb46*^{GFP+} mouse embryos at E14.5 (n = 7 embryos). **h.** *Zbtb46* mRNA relative to *Hprt* in cells sorted from the large intestine by qPCR (n = 5 mice). **i.** Quantification of cells from the large intestine of *Zbtb46*^{GFP+} mice (n = 6 or 7 mice). **j.** *Zbtb46* mRNA relative to *Hprt* in cells from the large intestine (n = 4 or 3 mice). **k.** *Zbtb46* mRNA relative to *Hprt* of *ex vivo* stimulated CCR6⁺ ILC3s (n = 4 mice). **l.** Quantification of ZBTB46 MFI in ILC3s from the intestine of CD, UC, or matched healthy donors (n = 14 individual healthy donors versus 15 CD donors; n = 7 individual healthy versus UC donors). Data in **a, b, c, e-k** are representative of two or three independent experiments; data in **d** are pooled from two independent experiments. Data are shown as the means ± S.E.M. Statistics are calculated by two-tailed unpaired Student's *t*-test in **d** (left panel), **f, g, i, and j**; two-tailed Mann-Whitney test in **d** (right panel); one-way ANOVA with Dunnett's multiple comparisons in **h** and **k**; two-tailed Wilcoxon test in **l**.




Figure 3. Zbtb46 restrains ILC3s and limits intestinal inflammation.

a. Quantification of Zbtb46 MFI among cells (*n* = 5 mice). **b.** Frequency of ILC3s among Lin⁻CD90⁺CD127⁺ cells (*n* = 8 or 7 mice). **c.** Quantification of CCR6⁺ ILC3s (*n* = 8 or 7 mice). **d.** Differential gene expression in CCR6⁺ ILC3s. Red points are significantly different. **e.** qPCR of indicated genes (*n* = 5 mice). **f,g.** Quantification of OX40L⁺CCR6⁺ ILC3s (*n* = 6 or 8 mice). **h.** Quantification of Th17 cells gated on FoxP3⁻CD4⁺ T cells (*n* = 4 or 5 mice). **i.** Quantification of IL-17A⁺CD4⁺ T cells (*n* = 4 or 5 mice). **j.** Quantification of Th17 cells (*n* = 4, 5, or 5 mice). **k.** Quantification of IL-17A⁺CD4⁺ T cells (*n* = 4, 5, or 5 mice). **l-p.** Mice were orally infected with *C. rodentium*. **l.** Quantification of Th17

cells at day 13 post infection (dpi) gated on FoxP3⁻CD4⁺ T cells (n = 5 or 4 mice). **m.** Quantification of IL-17A⁺CD4⁺ T cells from infected mice (n = 5 or 4 mice). **n.** Quantification of fecal colony-forming units (CFU) at 8 dpi (n = 5 mice). **o.** Colon length (n = 5 mice) at 13 dpi. **p.** H&E staining of the distal colon at 13 dpi. All data are on cells isolated from the large intestine unless otherwise noted. Data in **a, e, h, i, j, k, l-p** are representative of 3 or 4 independent experiments. Data are pooled from two independent experiments in **b, c,** and **g.** Data are shown as the means ± S.E.M in **a-c, e, g, i-o,** and means ± S.D. in **h.** Statistics are calculated by two-tailed unpaired Student's *t*-test in **a-c, e, g, i, l-o;** one-way ANOVA with Dunnett's multiple comparisons in **j** and **k.** Scale bar: 100 μm.




Figure 4. Zbtb46⁺ ILC3s are non-redundant in controlling intestinal inflammation.

a. UMAP of *I122* expression among RORγt⁺ immune cells from the large intestine. Dash circle indicates Zbtb46⁺ ILC3s. **b.** Quantification of IL-22⁺ cells among Zbtb46⁺ versus Zbtb46⁻ ILC3s (n = 5 mice). **c.** *Zbtb46* mRNA relative to *Hprt* in ILC3s sorted from the large intestine of *I122*-eGFP reporter mice (n = 5 mice). **d,e.** Flow plots and the frequency of ILC3s in Lin⁻CD90⁺CD127⁺ cells from the large intestine (n = 4 or 5 mice). **f,g.** Flow plots and quantification of ILC3 subsets in the large intestine (n = 4 or 5 mice). **h.** Cell numbers of ILC3 subsets in the large intestine (n = 4 or 5 mice). **i-o.** Mice were orally infected with *C. rodentium*. **i.** The frequency of ILC3s in Lin⁻CD90⁺CD127⁺ cells from the large intestine at 14 dpi (n = 4 or 7 mice). **j.** Quantification of ILC3 subsets in the large intestine at 14 dpi

(n = 4 or 7 mice). **k.** Fecal CFU at 10 dpi (n = 5 mice). **l.** Flow plots and quantification of Th17 cells gated on FoxP3⁻CD4⁺ T cells from the large intestine at 14 dpi (n = 5 mice). **m.** Quantification of IL-17A⁺ cells in CD4⁺ T cells from the large intestine at 14 dpi (n = 5 mice). **n.** Colon length at 14 dpi (n = 4 or 7 mice). **o.** H&E staining of the distal colon at 14 dpi. Data in **b-n** are representative of two or three independent experiments. Data are shown as the means ± S.E.M in **b, c, e, g-k, m, n**, and means ± S.D. in **l**. Statistics are calculated by two-tailed unpaired Student's *t*-test in **b, e, g-k, m, n**, and two-tailed paired *t*-test in **c**. Scale bar: 100 μm.